Macro­Gen­ics flips over an OS dud for can­cer drug Mar­gen­za in sur­pris­ing turn­around from ear­li­er da­ta

Can­cer play­er Macro­Gen­ics scored a big win with its full ap­proval for an­ti-HER2 drug Mar­gen­za last win­ter based on a head-to-head matchup with breast can­cer ti­tan Her­ceptin. Now, a fuller look at Mar­gen­za’s sur­vival da­ta months af­ter that ap­proval could spell a rough road ahead for the drug.

Macro­Gen­ics’ Mar­gen­za af­ter chemo failed to sig­nif­i­cant­ly ex­tend the lives of pa­tients with ad­vanced HER2-pos­i­tive breast can­cer af­ter two or more lines of pri­or ther­a­py com­pared with Roche’s Her­ceptin. Those da­ta fly counter to the drug’s clin­i­cal­ly mean­ing­ful pro­gres­sion-free sur­vival da­ta that won it its FDA ap­proval back in De­cem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER